Printer Friendly

Ursodeoxycholic acid influences the expression of [p27.sup.kip1] but not foxO1 in patients with non-cirrhotic primary biliary cirrhosis.

1. Introduction

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by an autoimmune-mediated inflammatory destruction of biliary epithelial cells [1-4] of the small intrahepatic small bile ducts. The standard care in PBC consists of the oral administration of ursodeoxycholic acid (UDCA) [5]. UDCA has been shown to improve clinical and biochemical indices in a variety of liver diseases, but the precise mechanism by which UDCA improves liver function remains unclear. Nevertheless, UCDA regulates the endogenous secretion of bile acid, reduces the cytotoxicity of endogenous bile acids, modulates the production of inflammatory cytokine, is protective against oxidative stress, and inhibits cell apoptosis [6, 7]. Recent reports have denoted another important role of UDCA as a key modulator of cell cycle [8].

The liver possesses a notable capacity to regenerate after partial resection until it achieves its primary size. Contrary to most cell types, mature hepatocytes preserve significant proliferative potential even after terminal differentiation. Recent data have convincingly demonstrated that the cell cycle regulator [p27.sup.kip1] contributes to the inhibition of proliferative activity of differentiated hepatocytes. [p27.sup.kip1] is a member of Cip/Kip family of broad spectrum cyclin dependent kinase (Cdk) inhibitors which suppress cell cycle progression in different cell types by negative regulation of Cdks. [p27.sup.kip1] appears to regulate the G1/S transition either by the prevention of Cdk-dependent phosphorylation of pRb [9,10] or by inhibition of activity of E-Cdk2 and A-Cdk2 cyclin complexes in mature nonproliferative hepatocytes [11]. During the development of rat liver, [p27.sup.kip1] is strongly expressed in fetal liver and declines afterwards. However, relatively moderate levels of p27 can be detected in differentiated quiescent hepatocytes. The increased number of hepatocytes noted in p27 knockout mice further underlines the important role of this gene in liver regeneration and makes it an appealing target in liver research [12].

The liver plays a crucial role in adaptation to stress. One of the most important stress response pathways is regulated by FoxO transcription factors. The FoxO subfamily composes of 4 members (FoxO1, FoxO3a, FoxO4, and FoxO6) and is characterized by the forkhead DNA-binding domain and broad physiological functions [13, 14]. In response to a variety of external stimuli, FoxOs orchestrate gene expressions involved in oxidative-stress resistance, DNA repair, and glucose metabolism and function to prevent cellular proliferation [15]. A FoxO subfamily of transcription factors appears to be important as positive regulator of [p27.sup.kip1] expression [14,16]. Although the role of FoxO transcription factors as critical modulators of the cell cycle homeostasis has been previously demonstrated in different cell types, the study of its expression in liver tissue has been limited so far to research carried out on cultured hepatocytes [17] or stellate cells [18].

We hypothesized that an activated FoxO1/[p27.sup.kip1] signaling axis can hinder the efficacy of cellular regeneration induced by early pathological changes specific for PBC. Knowing that hepatocytes are able to arrest reversibly a cell growth, we focused on the genes that repeatedly correlate with modulation of the cell cycle. To the best of our knowledge, this is the first study to investigate in great detail the expression of FoxO1 and [p27.sup.kip1] in human liver tissue of patients with non-cirrhotic and cirrhotic PBC. Finally, the interrelationship between FoxO1 and its possible downstream target [p27.sup.kip1] was investigated in the livers of mice harboring a conditional deletion of FoxO1/3a/4.

2. Materials and Methods

2.1. Liver Tissue. Human liver tissue specimen from noncirrhotic and cirrhotic liver disease patients was analyzed. The cirrhotic groups included 23 patients with PBC, 9 with primary sclerosing cholangitis (PSC) and 9 with alcoholic liver disease (ALD). A fourth group of non-cirrhotic PBC (n = 26) was also studied. Liver tissue specimens were obtained from non-cirrhotic PBC when they underwent routine percutaneous liver biopsies for histological assessment of the stage of the disease and fibrosis scoring. The cirrhotic groups liver tissue specimens were obtained from explanted livers of patients with PBC, PSC, and ALD who underwent liver transplantation.

Amongst the 26 non-cirrhotic PBC patients, 10 were receiving ursodeoxycholic acid (UDCA) in the dose 13-15mg/kgb.w. before obtaining liver tissue, while 16 were UDCA-naive. Samples (n = 19) from liver tissues with no macroscopic changes obtained during large margin resections of hepatocellular carcinoma served as controls. Patients and controls were matched for age and sex and an informed consent was obtained from each patient. The study protocol was approved by the ethics committee of Pomeranian Medical University and conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Table 1 summarizes clinical and laboratory features of the study participants.

2.2. Human Liver Tissue Preparation. Liver tissue (~1[cm.sup.3]; from controls, ALD, PSC, and cirrhotic PBC) was immediately frozen in liquid nitrogen and stored at -75[degrees]C until used. Tissue specimens obtained by percutaneous needle liver biopsy (non-cirrhotic PBC) were cut into two pieces. One part (2-3 [mm.sup.2]) was stored in RNA later (AM7021; Applied Biosystems, Carlsbad, CA, USA) and the second one was fixed in 10% neutral-buffered formalin and subsequently embedded in paraffin for histological assessment. Serial sections (5 [micro]m) were stained with hematoxylin and eosin. The liver tissue from non-cirrhotic PBC patients was analyzed by a pathologist blinded to the clinical and laboratory features of the included subjects (Table 2).

2.3. Animal Study: Generation of Mx-[Cre.sup.+]: FoxO1/3/[4.sup.L/L] Mice. All experimental procedures that involved animals were approved by the York University Animal Care Committee. Mice harboring the interferon-inducible transgene Mx-Cre in a FoxO1/3/[4.sup.L/L] background were generated as previously described [19]. Cre expression and subsequent FoxO1/3/4 excision was induced in 4-5-week-old mice by three intraperitoneal injections of 300 [micro]g polyinosinepoly-cytidylic (pIpC, Sigma-Aldrich) administered every other day over 5 days. pIpC was also administered to Mx-Crelittermate controls. All mice were housed and maintained in a pathogen-free animal facility in microisolator cages. Animals were monitored daily and were sacrificed at designated times after induction with pIpC. Murine livers extraction was performed under aseptic conditions and isoflurane anesthesia, at minimum of 2 weeks following the final injection of pIpC. Total RNA and proteins were extracted directly from the fresh tissue.

2.4. RNA Extraction and cDNA Synthesis. Total RNA from human and murine liver tissues was extracted using the RNeasy Mini kit (Qiagen, Valencia, USA), according to the manufacturer's protocol. The isolated RNA was stored at -75[degrees]C until used. cDNA synthesis was carried out using Superscript II RT kit (Invitrogen, Carlsbad, CA, USA) according to the protocol previously described [20]. Newly synthetised cDNA was stored at -20[degrees]C.

2.5. Quantification of Gene Expression Using Real-Time PCR. The expression of specific target genes was measured by quantitative real-time PCR using commercially available Gene Expression Assays and 7500 Fast Real-Time PCR System (Applied Biosystems). The following assays were used in the study: human FoxOl (Hs00231106_m1); human [p27.sup.kip1] (Hs00153277_m1); murine FoxOl (Mm00490672_m1); murine [p27.sup.kip1] (Mm00438168_m1), and control human GAPDH (Hs99999905_m1) and murine GAPDH (Mm99999915_g1). A 20 pL reaction mixture contained 10 [micro]L of TaqMan Gene Expression PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 2 [micro]L diluted cDNA template, and 1 [micro]L of the probe/primer mix. The fluorescence data were analyzed with 7500 Software v2.0.2. (Applied Biosystems, Carlsbad, CA, USA). The expression of target genes was calculated using the [DELTA][DELTA]Ct method of relative quantification.

2.6. Protein Expression Analysis. Proteins from human (control n = 19; ALD n= 9; PSC n = 9; and cirrhotic PBC n = 23) and murine liver tissue were extracted through homogenization in an ice-cold RIPA buffer (50 mM Tris-HCl pH = 8, 150 mM NaCl, 1% NP-40, 0.5% NaDOC, 0.1% SDS, 1mM EDTA, 100 mM PMSF, and 100 mM NaF) containing protease inhibitor cocktail and PhosSTOP (Roche Diagnostics GmbH, Mannheim, Germany). Protein quantification was made using the bicinchoninic acid assay (Micro BCA Protein Assay Kit; Thermo Scientific, Waltham, MA, USA). 80 [micro]g of total protein extracts from each liver sample was electrophoresed in SDS polyacrylamide gels. Subsequently the gels were blotted into PVDF membranes (Thermo Scientific, Rockford, IL, USA) under semidry transfer conditions. Membranes were blocked overnight (4[degrees]C) with TBST containing 5% (w/v) milk (Merck) and then probed using the following primary antibodies: anti-FoxO1 (9454; Cell Signaling, 1 : 500 dilution), anti- [p27.sup.kip1] (sc-1641; Santa Cruz, 1: 500), anti-[alpha]/[beta]tubulin (2148, Cell Signaling, 1:1000 dilution), and anti-[beta]actin (sc-47778; Santa Cruz, 1: 1000 dilution). For the detection of antigen-antibody complexes, peroxidase conjugated anti-rabbit secondary antibody (NA9340V, Amersham, GE Healthcare, UK; 1 : 5000 dilution) or anti-mouse secondary antibody (NA9310V, Amersham; 1 : 5000 dilution) was used. Protein expression was detected using an enhanced chemiluminescence detection system (Chemiluminescent HRP Substrate, Millipore, Billerica, MA, USA) and visualized on autoradiographic films (Amersham Hyperfilm ECL). Band densities were quantified by densitometry (GeneSnap ver. 7.01 software; Syngene, Cambridge, UK) after normalization to [alpha]/[beta]-tubulin or [beta]-actin.

2.7. Statistical Analysis. Statistical analysis was performed with ANOVA and Fisher's PSLD using StatView software version 5.0 (SAS Institute Inc. Cary, NC, USA). Data were expressed as mean [+ or -] SE for at least nine separate experiments. Results were considered statistically significant when two-side P values were less than 0.05.

3. Results

3.1. Expression of FoxOl. The qPCR analysis of human liver tissue showed a notable upregulation of FoxOl mRNA in cirrhotic liver tissue of patients with PBC compared to controls (8.5-fold increase; P < 0.0001). The levels of

FoxO1 mRNA in PSC and ALD patients were comparable to those of controls (Figure 1(a)). Western blot analysis revealed no statistically significant difference in FoxO1 protein levels between cirrhotic patients with PBC and controls. Interestingly, the levels of FoxO1 protein were decreased in PSC (2.5fold decrease versus control; P < 0.05) and in ALD (3.7-fold decrease versus control; P < 0.005) Figure 1(b)).

3.2. Expression of [p27.sup.kip1]. [p27.sup.kip1] was previously described as the downstream target of FoxO1. Therefore, [p27.sup.kip1] mRNA and protein levels were also examined. The results ofquantitative PCR showed a significant increase of [p27.sup.kip1] mRNA levels in non-cirrhotic and cirrhotic patients with PBC compared to controls (2.1 [+ or -] 0.2 versus 1.3 [+ or -] 0.3, P = 0.04 and 9.3 [+ or -] 2.3 versus 1.3 [+ or -] 0.3, P = 0.0001,resp.) (Figure 2(a)). [p27.sup.kip1] mRNA levels did not correlate with stages of fibrosis.

The levels of [p27.sup.kip1] mRNA in ALD and PSC were comparable to control values (Figure 2(a)). Western blot analyses of tested liver specimens showed statistically significant upregulation of [p27.sup.kip1] protein levels in cirrhotic PBC, PSC, and ALD (3.6-fold, 2-fold, and 4.5-fold increase, resp.; P < 0.0001, P < 0.05, and P < 0.005 versus controls, resp.) (Figure 2(b)).

3.3. Expression of FoxOl and [p27.sup.kip1] in Mx-[Cre.sup.+/-]: FoxOl/3/4 Mice. Pharmacologically induced deletion of FoxO1/3/4 genes resulted in marked decrease of FoxO1 expression on both mRNA (2.4-fold decrease; P < 0.05) and protein levels (3.2-fold decrease; P < 0.05) in Mx-[Cre.sup.+]: FoxO1/3/4 mice when compared to the control Mx-[Cre.sup.-]: FoxO1/3/4 mice group. Furthermore, a significant decrease in the expression of a downstream gene [p27.sup.kip1] was observed at mRNA level (7.5-fold decrease at Mx-[Cre.sup.+] versus Mx-[Cre.sup.-] mice, P < 0.001). No significant changes of [p27.sup.kip1] protein levels were noted in liver tissues of Mx-[Cre.sup.+]: FoxO1/3/4 mice compared to Mx-[Cre.sup.-] (Figures 3(a) and 3(b)).

3.4. Expression of FoxO1 and [p27.sup.kip1] in Patients Treated with UDCA and UDCA Naive. UDCA treatment of non-cirrhotic PBC patients did not affect FoxO1 mRNA level but the [p27.sup.kip1] mRNA levels were significantly lower in UDCA-treated versus UDCA naive non-cirrhotic PBC patients (1.4[+ or -] 0.2 versus 2.3 [+ or -] 0.3 UDCA naive; P = 0.036) (Figure 4). In patients with PSC, UDCA treatment did not affect the mRNA and protein levels of [p27.sup.kip1] or FoxO1 (data not shown).

4. Discussion

In this study, we demonstrated an enhanced expression of [p27.sup.kip1] mRNA in non-cirrhotic and cirrhotic PBC livers and noted that the level of [p27.sup.kip1] transcript was much higher in cirrhotic versus non-cirrhotic patients with PBC. The FoxO1 mRNA expression was also significantly increased in cirrhotic PBC. Intriguingly, these changes were specific for PBC as they were not observed in cirrhotic livers from patients with ALD, as well as PSC, another autoimmune cholestatic liver disease. These data led us to speculate that an increased expression of FoxO1 transcription factor with an increased level of cell cycle inhibitor [p27.sup.kip1] may significantly contribute towards suppression of hepatocyte proliferation. Consequently, this may result in insufficient liver regeneration. Our study has also convincingly shown that UDCA administration at early stages of PBC significantly attenuates [p27.sup.kip1] expression in human liver. However, FoxO1 levels remained unaffected.

Our data suggesting a PBC-specific increase of FoxO1 mRNA levels in cirrhotic livers is intriguing. The interpretation of this finding needs to be treated with caution, as it is well known that the synthesis of functional FoxO1 protein is controlled by multiple posttranslational modifications [21]. A thorough assessment of many upstream events that affect the amount of this protein in liver diseases is warranted to better understand the differentiation seen in cirrhotic livers from PBC compared to PSC and ALD. Nevertheless, it could be speculated that one of the potential mechanisms that could account for these findings may be disease-specific downregulation of FoxO1 transcript stability by miRNAs [22, 23].

The role of FoxO1 as the upstream modulator of [p27.sup.kip1] gene was shown in various cell lines including murine lymphocytes, bone marrow cells, and human peripheral blood eosinophils [14, 16, 24]. Recently, the importance of FoxO1 in transcription regulation of [p27.sup.kip1] expression was confirmed in cultured hepatic stellate cells (HSC) [25]. The published data have suggested a potential role of FoxO1 in hepatic fibrosis, as a constitutive activation of FoxO1 in vitro accompanied by the enhanced expression of [p27.sup.kip1] has been demonstrated. The result of this led to the suppression of HSC proliferation, while the dominant negative form of FoxO1 and downregulation of [p27.sup.kip1] had an opposite effect [25]. As this single study was focused on the investigation of cultured HSC, it will be challenging to draw generic conclusions applied to in vivo conditions of unfractioned liver cells containing less than 5% HSCs.

A negative regulator of the transition from G1 to S phase (i.e., [p27.sup.kip1] protein) was shown to be abnormally expressed in dysplasia associated with Barrett's esophagus, sporadic colorectal adenomas, and inflammatory bowel disease-associated neoplasia [26]. Significantly lower p27 expression is commonly associated with a worse prognosis. On the other hand, the overexpression of [p27.sup.kip1] in glioblastoma cell lines induced cell cycle arrest [27]. Also, the studies of [p27.sup.kip1] expression in human liver were mostly done in the context of its prognostic significance in intrahepatic cholangiocarcinoma [28]. Recent liver regeneration studies indicate that stimulation in hepatocyte S-phase progression by adenovirus delivery of FoxM factor which was associated with diminished [p27.sup.kip1] protein level was sufficient to reestablish proliferation of regenerating hepatocytes [29]. To the best of our knowledge there is no report on the expression of this cell inhibitor in autoimmune cholestatic liver diseases. The current study investigated [p27.sup.kip1] expression in different stages of PBC. The advanced stage of the disease was accompanied by the highest [p27.sup.kip1] mRNA and protein levels. It must be emphasized though that amongst non-cirrhotic patients with PBC [p27.sup.kip1] increase was independent of the degree of fibrosis.

While cirrhotic PSC and ALD liver tissues did not show changes in [p27.sup.kip1] mRNA levels, a significant increase in [p27.sup.kip1] protein levels was noted in cirrhotic liver tissues independently of the origin of the underlying liver disease. These data could suggest that progression to advanced stages relates to an abrogation of cellular proliferation. Particularly for the liver diseases studies, it could be argued that PBC, PSC, and ALD are characterized by a decreased capacity of cellular regeneration, which could be caused by high concentration of cell cycle inhibitor [p27.sup.kip1] in liver cells.

In order to confirm previous results suggesting that expression of [p27.sup.kip1] is regulated by FoxO1 transcription factor, we utilized a model of transgenic mice. Inducible somatic deletion of FoxO genes in mice revealed that there is no direct effect of FoxO1 on [p27.sup.kip1] expression in murine liver tissue. Jointly, our human and animal studies indicate that in PBC, PSC, and ALD the upregulated expression of [p27.sup.kip1] may not be dependent on its upstream activator FoxO1.

UDCA administration was reported to exert antiproliferative effects in the large intestine and colon carcinoma in patients with PBC or PSC [30, 31]; however, the mechanisms orchestrating these phenomena are not completely understood. In our study, the effect of UDCA treatment on FoxO1 or [p27.sup.kip1] expression was analyzed in the non-cirrhotic PBC patients. The analyses showed that transcript level of [p27.sup.kip1] was significantly reduced in response to UDCA treatment, further suggesting its potential effect on liver regeneration. Short-lived pharmacological agents that restrain [p27.sup.kip1] function could hypothetically be of use, as potential modality facilitating liver response to pathological stimuli.

In the animal model of colitis-associated colonic adenocarcinomas the anticarcinogenic effects of UDCA in vivo were demonstrated [8]. Loddenkemper et al. showed that UDCA treatment reversed the inflammation-related suppression of the cyclin dependent kinase inhibitor p27. However, the expression of p27 and the effects of UDCA in the dysplastic areas were not consistent. The apparent lack of consistency of these data with our results can be explained by the fact that the two sets of experiments were performed in different settings. Thus, reported data were obtained in an animal model of DSS-induced colon carcinomas, and it could be argued that the mechanism of UDCA effect on p27 expression may be quite distinct from that exerted in relation to our studies. Moreover, the evaluation of p27 level was based on immunohistological analysis which is only semiquantitative tool and the lack of mRNA and protein evaluations of p27 in that experimental setting do not permit for an in-depth conclusion. Of relevance to the current study, it is notable that, while cell cycle inhibitor p27 is expressed in many cell types, its unique role in cholestatic liver diseases has not been elucidated. UDCA regulates many physiological processes in a highly context-specific manner. In the context of UDCA effect on p27 expression, direct comparisons between animal carcinoma/inflamed region and liver tissue from PBC patients maybe misrepresentative. Therefore, there is a need for a direct analysis of the therapeutic impact of UDCA in particular disease settings. Such analyses can provide a better understanding of the observed phenomena.

The present study indicated that [p27.sup.kip1] may play an important role in inhibition of cell cycle during the progression of disease and that the expression of this cell cycle inhibitor is most likely FoxO1-independent. The FoxO1-[p27.sup.Kip1] pathway was identified as a crucial regulator of the progression of cell cycle; however, the FoxO1 is also an autonomously important factor either for differentiation or maintaining differentiated cells in a nonproliferative state even in the absence of p27 [32, 33]. Based on our data, in which we observed that FoxO1 expression was comparable amongst UDCA-treated and naive subjects, we suggested that UDCA affects the p27 expression independently of the FoxO1 transcription factor. This is a potentially interesting phenomenon and needs to be investigated further. Although the results of this work are pretty consistent, an increase of the number of samples tested from patients with ALD and PSC groups could strengthen the current results.

Taken these findings together, we suggest that increased expression of [p27.sup.kip1] may be a factor that suppresses regenerative proliferation. The observed attenuation of [p27.sup.kip1] expression in UDCA-treated patients with early PBC may exert a positive effect on liver regeneration due to enhanced cell proliferation, but this remains to be seen in future studies.


ALD:  Alcoholic liver disease
PBC:  Primary biliary cirrhosis
PSC:  Primary sclerosing cholangitis
UDCA: Ursodeoxycholic acid.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This study was supported by the Grant 2011/02/A/NZ5/00321 from National Science Centre in Poland.


[1] H. P. Dienes, A. W. Lohse, G. Gerken et al., "Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis," Virchows Archiv, vol. 431, no. 2, pp. 119-124, 1997

[2] A. Lleo, C. L. Bowlus, G.-X. Yang et al., "Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis," Hepatology, vol. 52, no. 3, pp. 987-996, 2010.

[3] G. M. Hirschfield, E. J. Heathcote, and M. E. Gershwin, "Pathogenesis of cholestatic liver disease and therapeutic approaches," Gastroenterology, vol. 139, no. 5, pp. 1481-1496, 2010.

[4] P. Invernizzi and M. E. Gershwin, "The genetic basis of primary biliary cirrhosis: premises, not promises," Gastroenterology, vol. 135, no. 4, pp. 1044-1047, 2008.

[5] K. Lindor, "Ursodeoxycholic acid for the treatment of primary biliary cirrhosis," The New England Journal of Medicine, vol. 357, no. 15, pp. 1476-1529, 2007

[6] P. Angulo, K. P. Batts, T. M. Therneau, R. A. Jorgensen, E. R. Dickson, and K. D. Lindor, "Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis," Hepatology, vol. 29, no. 3, pp. 644-647, 1999.

[7] C. M. P. Rodrigues, G. Fan, X. Ma, B. T. Kren, and C. J. Steer, "A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation," The Journal of Clinical Investigation, vol. 101, no. 12, pp. 2790-2799, 1998.

[8] C. Loddenkemper, S. Keller, M.-L. Hanski et al., "Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid," International Journal of Cancer, vol. 118, no. 11, pp. 2750-2757, 2006.

[9] A. Vidal and A. Koff, "Cell-cycle inhibitors: three families united by a common cause," Gene, vol. 247, no. 1-2, pp. 1-15, 2000.

[10] O. Coqueret, "New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?" Trends in Cell Biology, vol. 13, no. 2, pp. 65-70, 2003.

[11] G. P. Ilyin, D. Glaise, D. Gilot, G. Baffet, and C. Guguen-Guillouzo, "Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth," American Journal of Physiology--Gastrointestinal and Liver Physiology, vol. 285, no. 1, pp. G115-G127, 2003.

[12] K. Nakayama, N. Ishida, M. Shirane et al., "Mice lacking [p27.sup.Kip1] display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors," Cell, vol. 85, no. 5, pp. 707-720, 1996.

[13] Z. Tothova and D. G. Gilliland, "FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system," Cell Stem Cell, vol. 1, no. 2, pp. 140-152, 2007

[14] M. Stahl, P. F. Dijkers, G. J. P. L. Kops et al., "The forkhead transcription factor FoxO regulates transcription of [p27.sup.Kip1] and Bim in response to IL-2," Journal of Immunology, vol. 168, no. 10, pp. 5024-5031, 2002.

[15] H. Huang and D. J. Tindall, "Dynamic FoxO transcription factors," Journal of Cell Science, vol. 120, no. 15, pp. 2479-2487, 2007.

[16] P. F. Dijkers, R. H. Medema, C. Pals et al., "Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of [p27.sup.Kip1]," Molecular and Cellular Biology, vol. 20, no. 24, pp. 9138-9148, 2000.

[17] F. J. Barreyro, S. Kobayashi, S. F. Bronk, N. W. Werneburg, H. Malhi, and G. J. Gores, "Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis," The Journal of Biological Chemistry, vol. 282, no. 37, pp. 27141-27154, 2007

[18] M. Adachi, Y. Osawa, H. Uchinami, T. Kitamura, D. Accili, and D. A. Brenner, "The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells," Gastroenterology, vol. 132, no. 4, pp. 1434-1446, 2007

[19] J.-H. Paik, R. Kollipara, G. Chu et al., "FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis," Cell, vol. 128, no. 2, pp. 309-323, 2007

[20] M. Milkiewicz, E. Roudier, J. L. Doyle, A. Trifonova, O. Birot, and T. L. Haas, "Identification of a mechanism underlying regulation of the anti-angiogenic forkhead transcription factor FoxO1 in cultured endothelial cells and ischemic muscle," American Journal of Pathology, vol. 178, no. 2, pp. 935-944, 2011.

[21] K. E. van der Vos and P. J. Coffer, "FOXO-binding partners: it takes two to tango," Oncogene, vol. 27, no. 16, pp. 2289-2299, 2008.

[22] C. Haftmann, A.-B. Stittrich, E. Sgouroudis et al., "Lymphocyte signaling: regulation of FoxO transcription factors by microRNAs," Annals of the New York Academy of Sciences, vol. 1247, no. 1, pp. 46-55, 2012.

[23] I. K. Guttilla and B. A. White, "Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells," The Journal of Biological Chemistry, vol. 284, no. 35, pp. 2320423216, 2009.

[24] R. H. Medema, G. J. P. L. Kops, J. L. Bos, and B. M. T. Burgering, "AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through [p27.sup.Kip1]," Nature, vol. 404, no. 6779, pp. 782-787, 2000.

[25] M. Adachi, Y. Osawa, H. Uchinami, T. Kitamura, D. Accili, and D. A. Brenner, "The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells," Gastroenterology, vol. 132, no. 4, pp. 1434-1446, 2007

[26] S. Walsh, M. Murphy, M. Silverman et al., "p27 expression in inflammatory bowel disease-associated neoplasia: further evidence of a unique molecular pathogenesis," American Journal of Pathology, vol. 155, no. 5, pp. 1511-1518,1999.

[27] M. Schiappacassi, F. Lovat, V. Canzonieri et al., "[p27.sup.Kip1] expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis," Molecular Cancer Therapeutics, vol. 7, no. 5, pp. 1164-1175, 2008.

[28] N. Hashimoto, S. Yachida, K. Okano et al., "Immunohistochemically detected expression of [p27.sup.Kip1] and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas," Annals of Surgical Oncology, vol. 16, no. 2, pp. 395-403, 2009.

[29] X. Wang, K. Krupczak-Hollis, Y. Tan, M. B. Dennewitz, G. R. Adami, and R. H. Costa, "Increased hepatic Forkhead Box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished [p27.sup.Kip1] protein levels and increased Cdc25B expression," The Journal of Biological Chemistry, vol. 277, no. 46, pp. 44310-44316, 2002.

[30] L. Serfaty, A. de Leusse, O. Rosmorduc et al., "Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study," Hepatology, vol. 38, no. 1, pp. 203-209, 2003.

[31] D. S. Pardi, E. V Loftus Jr., W. K. Kremers, J. Keach, and K. D. Lindor, "Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis," Gastroenterology, vol. 124, no. 4, pp. 889-893, 2003.

[32] S. Majumdar, C. L. Farris, B. E. Kabat, D. O. Jung, and B. S. Ellsworth, "Forkhead Box O1 is present in quiescent pituitary cells during development and is increased in the absence of [p27.sup.Kip1]," PLoS ONE, vol. 7, Article ID e52136, 2012.

[33] H. S. Dengler, G. V. Baracho, S. A. Omori et al., "Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation," Nature Immunology, vol. 9, no. 12, pp. 1388-1398, 2008.

Malgorzata Milkiewicz, (1) Justyna Kopycinska, (1) Agnieszka Kempinska-Podhorodecka, (1) Tara Haas, (2) Dimitrios P. Bogdanos, (3) Elwyn Elias, (4) and Piotr Milkiewicz (5,6)

(1) Medical Biology Laboratory, Pomeranian Medical University, Aleja Powstancow Wlkp. 72, 70-111 Szczecin, Poland

(2) Angiogenesis Research Group, Faculty of Health, York University, Toronto, Canada

(3) Division of Transplantation Immunology and Mucosal Biology, Institute of Liver Studies, King's College London Medical School at King's College London Hospital, London SE5 9RS, UK

(4) Liver Unit, University of Birmingham, Birmingham B15 2TH, UK

(5) Liver Research Laboratories, Pomeranian Medical University, 70-111 Szczecin, Poland

(6) Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Warsaw Medical University, 02-092 Warsaw, Poland

Correspondence should be addressed to Malgorzata Milkiewicz;

Received 3 September 2013; Revised 12 November 2013; Accepted 9 December 2013; Published 5 February 2014

Academic Editor: Eirini I. Rigopoulou

TABLE 1: Clinical and laboratory data on analyzed patients.
P values between non-cirrhotic and cirrhotic patients with PBC.

                      PBC              PBC n = 23
                     n = 26

Gender (M/F)          0/26               5/18 *

Age (years)      54 [+ or -] 2       56 [+ or -] 2NS

Bilirubin        21 [+ or -] 6     114 [+ or -] 23 **
tot. ([micro]

ALP (U/L)       251 [+ or -] 36    644 [+ or -] 83 **

AST (U/L)        63 [+ or -] 11    175 [+ or -] 28 **

UDCA (Y/N)           10/16               23/0**

                   PSC n = 9           ALD n = 9

Gender (M/F)          6/3                 7/2

Age (years)      48 [+ or -] 5       54 [+ or -] 2

Bilirubin       133 [+ or -] 34     67 [+ or -] 32
tot. ([micro]

ALP (U/L)       541 [+ or -] 88     275 [+ or -] 38

AST (U/L)       204 [+ or -] 42    216 [+ or -] 138

UDCA (Y/N)            4/5                 0/9

Data shown are mean [+ or -] SE.

NS: not significant; * P < 0.05; ** P < 0.01 versus non-cirrhotic.

TABLE 2: Clinical data on non-cirrhotic patients with PBC who were
and were not treated with UDCA.

                         UDCA (+)           UDCA (-)

Gender (M/F)               0/10               0/16           NS

Age (years)           60 [+ or -] 2      51 [+ or -] 3       NS

Total bilirubin       22 [+ or -] 5      21 [+ or -] 9       NS

ALP (U/L)            292 [+ or -] 76    228 [+ or -] 38      NS

AST (U/L)             87 [+ or -] 24     51 [+ or -] 11      NS

Degree of                  3/7                11/5         0.027
fibrosis 0-1/2-3

Data shown are mean [+ or -]SE; NS: not statistically significant;
P > 0.05.
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Milkiewicz, Malgorzata; Kopycinska, Justyna; Kempinska-Podhorodecka, Agnieszka; Haas, Tara; Bogdanos
Publication:Journal of Immunology Research
Article Type:Report
Date:Jan 1, 2014
Previous Article:Exploring the innate immunological response of an alternative nonhuman primate model of infectious disease; the common marmoset.
Next Article:CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters